INNV vs. DCGO, SHCR, USPH, PNTG, CRHM, LFST, PRVA, GERN, QURE, and BHVN
Should you be buying InnovAge stock or one of its competitors? The main competitors of InnovAge include DocGo (DCGO), Sharecare (SHCR), U.S. Physical Therapy (USPH), The Pennant Group (PNTG), CRH Medical (CRHM), LifeStance Health Group (LFST), Privia Health Group (PRVA), Geron (GERN), uniQure (QURE), and Biohaven (BHVN). These companies are all part of the "medical" sector.
InnovAge vs.
InnovAge (OTCMKTS:INNV) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations and profitability.
DocGo has lower revenue, but higher earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.
InnovAge currently has a consensus target price of $6.48, suggesting a potential upside of 6.63%. DocGo has a consensus target price of $11.67, suggesting a potential upside of 33.64%. Given DocGo's stronger consensus rating and higher probable upside, analysts plainly believe DocGo is more favorable than InnovAge.
DocGo has a net margin of 7.85% compared to InnovAge's net margin of -5.57%. DocGo's return on equity of 12.80% beat InnovAge's return on equity.
In the previous week, DocGo had 2 more articles in the media than InnovAge. MarketBeat recorded 2 mentions for DocGo and 0 mentions for InnovAge. DocGo's average media sentiment score of 0.27 beat InnovAge's score of 0.09 indicating that DocGo is being referred to more favorably in the news media.
InnovAge received 118 more outperform votes than DocGo when rated by MarketBeat users. Likewise, 60.00% of users gave InnovAge an outperform vote while only 58.62% of users gave DocGo an outperform vote.
12.4% of InnovAge shares are owned by institutional investors. Comparatively, 36.9% of DocGo shares are owned by institutional investors. 0.3% of InnovAge shares are owned by insiders. Comparatively, 19.7% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
InnovAge has a beta of -0.01, suggesting that its share price is 101% less volatile than the S&P 500. Comparatively, DocGo has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.
Summary
DocGo beats InnovAge on 15 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INNV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InnovAge Competitors List
